[go: up one dir, main page]

NO20074964L - Pyrimidinderivater for behandling av hyperproliferative forstyrrelser - Google Patents

Pyrimidinderivater for behandling av hyperproliferative forstyrrelser

Info

Publication number
NO20074964L
NO20074964L NO20074964A NO20074964A NO20074964L NO 20074964 L NO20074964 L NO 20074964L NO 20074964 A NO20074964 A NO 20074964A NO 20074964 A NO20074964 A NO 20074964A NO 20074964 L NO20074964 L NO 20074964L
Authority
NO
Norway
Prior art keywords
treatment
pyrimidine derivatives
hyperproliferative disorders
compounds
hyperproliferative
Prior art date
Application number
NO20074964A
Other languages
English (en)
Inventor
Ming Wang
Alexander Hillisch
Julie A Dixon
Wenlang Fu
Donald Bierer
Dhanapalan Nagarathnam
Lei Zhang
Chunguang Wang
Lin Yi
Yuanwei Chen
Jianqing Chen
Brian R Bear
Michael Brands
Martin F Hentemann
Ann-Marie Bullion
Manoj Patel
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36624969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074964(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20074964L publication Critical patent/NO20074964L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Pyrimidin derivater med formel farmasøytiske sammensetninger som inneholder disse forbindelsene og fremgangsmåter for anvendelse av disse forbindelsene ved behandling av hyperproliferative sykdommer slike som kreft er beskrevet.
NO20074964A 2005-03-10 2007-10-02 Pyrimidinderivater for behandling av hyperproliferative forstyrrelser NO20074964L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66056105P 2005-03-10 2005-03-10
PCT/US2006/008779 WO2006099231A1 (en) 2005-03-10 2006-03-09 Pyrimidine derivatives for treatment of hyperproliferative disorders

Publications (1)

Publication Number Publication Date
NO20074964L true NO20074964L (no) 2007-12-06

Family

ID=36624969

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074964A NO20074964L (no) 2005-03-10 2007-10-02 Pyrimidinderivater for behandling av hyperproliferative forstyrrelser

Country Status (23)

Country Link
US (1) US20110098301A1 (no)
EP (1) EP1858882A1 (no)
JP (1) JP2008533042A (no)
KR (1) KR20080004488A (no)
CN (1) CN101151258A (no)
AR (1) AR053554A1 (no)
AU (1) AU2006223199A1 (no)
BR (1) BRPI0609022A2 (no)
CA (1) CA2601257A1 (no)
CR (1) CR9347A (no)
DO (1) DOP2006000061A (no)
EA (1) EA200701930A1 (no)
GT (1) GT200600105A (no)
IL (1) IL185498A0 (no)
MA (1) MA29377B1 (no)
MX (1) MX2007010102A (no)
NO (1) NO20074964L (no)
PE (1) PE20061067A1 (no)
TN (1) TNSN07322A1 (no)
TW (1) TW200724537A (no)
UY (1) UY29414A1 (no)
WO (1) WO2006099231A1 (no)
ZA (1) ZA200708591B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530386A (ja) * 2006-03-20 2009-08-27 バイエル・ヘルスケア・エルエルシー パクリタキセル組み合わせ物
EP2173722B1 (en) * 2007-07-26 2012-08-29 Novartis AG Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
AU2011310532B2 (en) 2010-10-01 2016-01-14 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
EA201390917A1 (ru) 2010-12-21 2013-12-30 Новартис Аг Дигетероарильные соединения в качестве ингибиторов vps34
PE20140502A1 (es) 2011-04-22 2014-05-02 Signal Pharm Llc Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas
KR20220143164A (ko) 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
CA2922657C (en) 2013-08-30 2022-04-12 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US9638690B2 (en) 2014-11-07 2017-05-02 The University Of British Columbia Compounds and compositions for use as alkylating agent sensors and methods of use thereof
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX2018001004A (es) 2015-07-24 2018-06-07 Celgene Corp Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este.
TWI609028B (zh) 2016-05-06 2017-12-21 財團法人工業技術研究院 共聚物與含其之樹脂組合物、封裝膜及封裝結構
BR112021002630A2 (pt) 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
CN111518078B (zh) * 2020-05-30 2021-02-26 南方医科大学 一种含氨基吡啶的嘧啶类化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3089480B2 (ja) * 1990-09-20 2000-09-18 ソニー株式会社 フリットシール装置
US6943172B2 (en) * 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US6924290B2 (en) * 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
WO2005035507A2 (en) * 2003-10-10 2005-04-21 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders

Also Published As

Publication number Publication date
US20110098301A1 (en) 2011-04-28
JP2008533042A (ja) 2008-08-21
TW200724537A (en) 2007-07-01
CN101151258A (zh) 2008-03-26
DOP2006000061A (es) 2006-09-30
KR20080004488A (ko) 2008-01-09
CA2601257A1 (en) 2006-09-21
MX2007010102A (es) 2007-10-12
EP1858882A1 (en) 2007-11-28
UY29414A1 (es) 2006-10-02
PE20061067A1 (es) 2006-11-30
IL185498A0 (en) 2008-01-06
AU2006223199A1 (en) 2006-09-21
CR9347A (es) 2007-12-17
BRPI0609022A2 (pt) 2010-01-12
MA29377B1 (fr) 2008-04-01
TNSN07322A1 (en) 2008-12-31
EA200701930A1 (ru) 2008-02-28
GT200600105A (es) 2007-02-14
AR053554A1 (es) 2007-05-09
ZA200708591B (en) 2009-01-28
WO2006099231A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
NO20074964L (no) Pyrimidinderivater for behandling av hyperproliferative forstyrrelser
MY149960A (en) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
NO20092658L (no) New compounds
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
PL1853602T3 (pl) Związki chemiczne
SI1853588T1 (sl) Kemične spojine
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
NO20091864L (no) Forbindelser for inhibering av mitotisk progresjon
IL181271A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
NO20080418L (no) Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application